Corporate restructuring news includes the transformation of CORDIS from a division of Cardinal Health, the acquisitions of Guidant by Boston Scientific and Abbott Laboratories, and appointments involving Cirtec Medical.
2 reports, 2 independent
Updated Aug 29
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Corporate restructuring news includes the transformation of CORDIS from a division of Cardinal Health, the acquisitions of Guidant by Boston Scientific and Abbott Laboratories, and appointments involving Cirtec Medical.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Alere, now part of Abbott Diagnostics, was previously associated with Cepheid.Sub-event
- Boston Scientific acquired Bolt Medical, where Brian Cook worked.Sub-event
CORDIS transformed from Cardinal Health; Guidant acquired by Boston Scientific and Abbott Laboratories; Shar Matin appointed CEO of Cirtec Medical.1 source
Keep exploring
The entities involved
-
CORDIS
European Commission's public repository and portal to disseminate information on all EU-funded research projects and their results
Nothing else this week.
-
Cardinal Health
Healthcare company
-
Guidant
Medical manufacturing company
Nothing else this week.
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
Coverage
Newest first; wire copies grouped- GlobeNewswireCirtec Medical Announces Appointment of New Chief Executive Officer BROOKLYN PARK, Minn., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Cirtec Medical, a leading strategic outsourcing partner for complex minimal
- StockStoryCAH Q2 Deep Dive: Specialty Expansion and Tariff Headwinds Shape Outlook Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q2 C